A Glucosylated BODIPY Uses the GLUT Channel to Target Cancer Cells in In Vitro and In Vivo Models

Area of Science:

• Biochemistry
• Organic Chemistry
• Medical Imaging

Background:

• Fluorescent probes conjugated to tumor-targeting molecules offer promise for precision cancer diagnostics and therapeutics.
• D-glucose residues target cancer cells due to their high energy demands, addressing limitations of tumor heterogeneity.
• BODIPY-based probes possess unique optical properties suitable for bioimaging applications.

Purpose of the Study:

• To develop and characterize a novel glucosylated BODIPY (Glc-BODIPY) probe.
• To evaluate the tumor-targeting capabilities of Glc-BODIPY in various cancer cell types.
• To assess the potential of Glc-BODIPY for both in vitro and in vivo cancer bioimaging.

Main Methods:

• Synthesis and characterization of the Glc-BODIPY conjugate.
• In vitro studies using different cancer cell lines to assess targeting specificity and uptake.
• In vivo experiments to evaluate tumor accumulation and imaging performance.

Main Results:

• Successful synthesis of the Glc-BODIPY probe.
• Demonstrated selective uptake and targeting of Glc-BODIPY in multiple cancer cell types.
• Evidence of Glc-BODIPY accumulation in tumors in vivo, suggesting potential for imaging.

Conclusions:

• Glc-BODIPY effectively targets a broad range of cancer cells by leveraging d-glucose recognition.
• The Glc-BODIPY probe demonstrates potential as a versatile tool for cancer bioimaging.
• This approach offers a promising strategy to overcome cancer heterogeneity in diagnostic and therapeutic applications.